Non-small cell lung cancer
Conditions
Interventions
Non-small cell lung cancer observation group:None
Sponsors
The Second Affiliated Hospital of Xi'an Jiaotong University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years old, pathologically confirmed advanced NSCLC (stage IV); 2. Plan to receive single-agent immunotherapy such as PD-1/PD-L1 monoclonal antibody; 3. Adequate tumor tissue (biopsy or surgical specimen) and peripheral blood samples can be obtained; 4. ECOG score = 3 months; 5. Sign the informed consent form; 6. Color Doppler echocardiography indicates that the cardiac ejection fraction is within the normal range, and other organ functions are good and meet the following indicators: hemoglobin >= 90g/L; white blood cells >= 3.5×10^9/L; platelets >= 100×10^9/L; neutrophils >= 1.5×10^9/L; aspartate aminotransferase not greater than 3 times the upper limit of normal; alanine aminotransferase not greater than 3 times the upper limit of normal; bilirubin not greater than 1.5 times the upper limit of normal; serum creatinine value not greater than 1.25 times the upper limit of normal.
Exclusion criteria
Exclusion criteria: 1.There are contraindications for immunotherapy (such as active autoimmune diseases, interstitial lung disease); 2.The patient has previously received the same type of immunotherapy; 3.The quality of tumor tissue or blood samples does not meet the standards; 4.The patient has other malignant tumors or has suffered from malignant tumors other than lung cancer within the past 5 years; 5.The patient has serious diseases other than non-malignant tumors that affect the patient's compliance or put the patient at risk for immunotherapy; 6.Severe liver dysfunction, liver function classification (Child-Pugh) grade C; 7.Severe heart dysfunction, with heart function at grade III or above; 8.Severe kidney dysfunction, including patients in the end-stage of renal failure or in the uremic stage
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival period;Objective remission rate(ORR);Drug sensitivity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival ; | — |
Countries
China
Contacts
Public ContactLi Yong
The Second Affiliated Hospital of Xi'an Jiaotong University
Outcome results
None listed